Breaking News

Sunshine Biopharma Begins CMO Negotiations

March 14, 2013

Seeks maker for preclinical studies of breast cancer drug

Sunshine Biopharma Inc. has initiated negotiations with several CMOs for the GMP manufacture of 1kg of Adva-27a, the company's lead drug in development for the treatment of breast cancer that has become resistant to current anti-cancer therapies.
 
The supply of Adva-27a will be used to complete the upcoming animal toxicity studies and plans to file an IND to proceed with the planned Phase I trial. The company intends to make any leftover material available for compassionate-use programs.
 
"We are excited to be at the stage of conducting GMP manufacturing of our drug," said Dr. Steve N. Slilaty, president and chief executive officer of Sunshine Biopharma. "The filing of our process patent to protect Adva-27a manufacturing in January this year allowed us to quickly move forward and securely share information with CMOs to supply us with kilogram quantities of Adva-27a to complete the data for the IND application and conduct Phase I clinical trials. The excitement is growing stronger at Sunshine Biopharma as we move towards completion of the IND-Enabling studies and the filing of our IND application."

Related Contract Manufacturing:

Related Packaging:

Related Compliance:

  • Predictive Analytics and the Future of RBM

    Rajneesh Patil, Senior Director, RBM and Analytics, QuintilesIMS||January 23, 2017
    How advances in Risk-Based Monitoring will enable a more proactive approach to identify and mitigate potential risks

  • The Growing Realm of Real-World Data

    Kristin Brooks, Contract Pharma||November 8, 2016
    PPD's Evidera acquisition aims to help clients address the growing demand for evidence from regulators and payers

  • Mastering Immunotherapy Clinical Trials: Dosing and Response

    Mastering Immunotherapy Clinical Trials: Dosing and Response

    Kristin Brooks, Contract Pharma||August 1, 2016
    Andrew Zupnick of Novella Clinical provides insights into dosing and measuring response in immunotherapy clinical trials